Journal
PHARMACOGENOMICS
Volume 20, Issue 16, Pages 1119-1124Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/pgs-2019-0093
Keywords
ALDH3A1 genotype; cyclophosphamide; CYP2B6 genotype; hepatotoxicity
Categories
Funding
- Key Research Program of China Bureau of Health Care [W2016ZD01]
Ask authors/readers for more resources
As a widely used alkylating agent, cyclophosphamide often leads to various toxicities. Severe hepatotoxicity has been rarely reported in breast cancer patients receiving chemotherapy containing cyclophosphamide. Differences in cyclophosphamide metabolism may contribute to variability in adverse events of patients. Here, we report on a case of a 68-year-old Chinese female with breast cancer who experienced severe and prolonged hepatotoxicity induced by cyclophosphamide. Pharmacogenetic tests showed that she was a carrier of CYP2B6*7 allele and this is the first case of a CYP2B6*7 variant in the Han Chinese population so far reported. In addition, the patient was also a carrier of an ALDH3A1*2 variant potentially contributing to the occurrence of hepatotoxicity. CYP2B6 and ALDH3A1 genotyping may play a role in guiding cyclophosphamide therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available